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To the Editor:
We applaud Oldenburg and colleagues for the successful imple-
mentation of a community-based intervention to curtail cardiovas-
cular disease (CVD) (1). The authors promote the increased use of
aspirin for primary prevention (the aim of which is to reduce the
risk for a first heart attack or stroke) among people who meet the
criteria  established  by  the  2009 US Preventive  Services  Task
Force. However, although their intervention was effective, we be-
lieve  the  use  of  aspirin  for  primary  prevention  should  be  ap-
proached with caution: trials of aspirin use in primary prevention
have demonstrated only a modest improvement in clinical out-
comes.
Consistent  with  various  meta-analyses,  Raju  and  colleagues
showed that aspirin was associated with a slight reduction in over-
all  mortality  (relative  risk,  0.94  [95%  confidence  interval,
0.88–1.0]); absolute risk reduction, 0.09%) but had no effect on
CVD mortality (2). In another investigation, a reduction in the risk
for negative CVD outcomes was not demonstrated when low-dose
aspirin was used for the primary prevention of atherosclerotic
events among patients with type 2 diabetes (3).
Review of these and other trials led the Food and Drug Adminis-
tration in May 2014 to deny a request from Bayer Healthcare to
change aspirin’s label to indicate use for primary prevention of
CVD. The agency stated that the use of aspirin for primary CVD
prevention is not supported by the evidence and that “there are ser-
ious risks associated with the use of aspirin, including increased
risk of bleeding in the stomach and brain, in situations where the
benefit of aspirin for primary prevention has not been established”
(4). In the design of the study by Oldenburg and colleagues, no
consideration was extended to patient factors that would deem the
use of aspirin inappropriate because of an increased risk of bleed-
ing or other contraindications (1). The US Preventive Services
Task Force  is  reviewing the  role  of  aspirin  in  people  without
known CVD to assess changes in rates of myocardial infarction
(MI), stroke, death from MI or stroke, and all-cause mortality, po-
tentially further relegating aspirin to a lesser role in the primary
prevention of CVD.
Although the community-based program described by Oldenburg
and colleagues was effective in increasing aspirin therapy among
patients at risk for CVD, implementation of established therapies
such as statins may prove to be more valuable. In a comparison of
aspirin and statins for the primary prevention of CVD, Dietrich
and Davis concluded that statins have a better risk-to-benefit pro-
file; in their evaluation, aspirin therapy resulted in the absolute re-
duction of major CVD events by 0.1%, whereas statin therapy res-
ulted in an absolute reduction of 1% to 2% (5). An assessment by
Austin and colleagues of the effects on mortality of underprescrib-
ing statins showed missed opportunities in the secondary preven-
tion of MI. In their study of 7,285 survivors of acute MI (AMI)
discharged from 102 hospitals in Ontario, Canada, they concluded
that modest increases in statin prescribing among patients least
likely  to  receive  a  prescription  at  discharge  could  lead  to  de-
creases in post-AMI mortality at the population level (6). Further-
more, because the risk for gastrointestinal bleeding and intracrani-
al hemorrhage (2 of the most serious adverse events associated
with aspirin) is 100 times the risk for rhabdomyolysis and hemor-
rhagic stroke (2 of the most serious adverse events associated with
statins), targeting statin therapy for intervention seems prudent (5).
Although the study by Oldenburg and colleagues highlights the
potential success of community-based interventions in promoting
the primary prevention of CVD, we advocate the use of therapies
that have better, proven effects than aspirin has.
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